SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                       Date of Report: September 16, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                        Delaware                    52-1555759
               (State of Incorporation)            (I.R.S. Employer
                                                   Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.



MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated September 15, 1999:



                 MEDIMMUNE LICENSES CATALYTIC ANTIBODY TO TREAT
                         COCAINE OVERDOSE AND ADDICTION

Gaithersburg,  MD, September 15, 1999 -- MedImmune,  Inc.  (Nasdaq:  MEDI) today
announced  that it has  entered  into an  exclusive  licensing  agreement  and a
research  collaboration with Columbia  University to develop and commercialize a
catalytic  antibody  against cocaine to treat overdose and addiction.  Under the
terms of the agreements,  MedImmune will be responsible for worldwide  research,
clinical  development,   manufacturing  and  commercialization  of  any  product
resulting from the  collaboration.  MedImmune will pay a one-time license fee to
Columbia,  and will  make  milestone  and  royalty  payments  based on  clinical
development progress and sales of resulting products.  Ixsys, Inc. will optimize
the primary product candidate as part of the four-product  antibody alliance the
company entered into with MedImmune in February 1999.

"The  challenge of treating  cocaine  addiction  with specific  antibodies is to
maintain a circulating  therapeutic  level of the antibody as the cocaine target
is depleted,"  commented  Scott Koenig,  M.D.,  Ph.D.,  Senior Vice President of
Research at MedImmune.  "We believe that catalytic  antibodies,  which both bind
and degrade  the target,  and free the  antibody to bind to  additional  cocaine
molecules,  may  provide  the  solution to that  problem.  A product  with these
characteristics  may prove to be a possible option to treat cocaine overdoses or
as an aid to breaking cocaine addiction."

Cocaine  specifically  blocks the reuptake of several  neurotransmitters  in the
brain including dopamine, which is associated with emotional response,  movement
and the ability to experience pleasure.  The drug binds to dopamine receptors in
the brain,  which blocks  reabsorption and increases both the amount of dopamine
and the number of receptors in the brain. This artificially  induced increase in
levels of dopamine causes  increased  activation in the brain's pleasure center,
causing euphoria.  Addiction occurs with continued use of cocaine,  as the brain
can no longer respond to natural reward stimulation and is forced to rely on the
drug to maintain the artificial high. At the extremely high  concentrations seen
in drug overdose, the drug binds to multiple receptors in the nervous system and
the  cardiovascular  system,  possibly causing  arrhythmia and sudden death. MAb
15A10,  a  catalytic  antibody,  has been shown to bind,  cleave and release the
degraded  cocaine in vitro,  thus freeing  itself for further  cocaine  binding.
Additionally,  the antibody has been shown to block the  reinforcing  effects of
cocaine and provide protection from cocaine-induced seizures and sudden death in
animal models.

"Our work to date with 15A10 has demonstrated the antibody's ability to catalyze
free  cocaine in an animal  model,"  added  Donald W.  Landry,  M.D.,  Associate
Professor  of Medicine and Director of Clinical  Pharmacology  and  Experimental
Therapeutics  at the  Columbia  University  College of  Physicians  and Surgeons
Department of Medicine.  "We believe that this new collaboration  with MedImmune
will allow both parties to further develop this antibody as possible therapy for
recovering  addicts or as treatment  for cocaine  overdose.  Cocaine  abuse is a
serious  problem,  both in the U.S.  and abroad,  and we are  excited  about the
opportunity to collaborate with MedImmune to address this issue." 

Since 1980,  over  40,000,000  Americans have used cocaine or crack,  the street
name given to cocaine  processed  to a free base for  smoking.  An  estimated  2
million  people  are  addicted  to  cocaine,  and there  are over  four  million
estimated regular users of the drug. Cocaine overdose is the most frequent cause
of addiction  related  emergency  room  admissions in the U.S. and Europe,  with
approximately  150,000 and 100,000  admissions,  respectively,  in 1998.  A 1998
survey  funded by the  National  Institute  on Drug Abuse found that the rate of
current cocaine use in 1996 was highest in the 18 to 25 age group (2.0 percent).
The rate of use for this age  group  was  significantly  higher  in 1996 than in
1995,  when it was 1.3  percent.  The same survey found that the  proportion  of
high-school  seniors who have used cocaine at least once in their  lifetimes has
increased  from a low of 5.9  percent  in  1994  to 8.7  percent  in  1997.  The
Physician  Leadership on National  Drug Policy,  addressing  the potential  cost
benefit of  treatment,  recently  reported that  approximately  seven dollars is
saved in medical and  societal  costs for every  dollar  spent on  treatment  of
addiction.  Current  treatment  options  for cocaine  addiction  are limited and
include treatment medications and behavioral interventions,  including cognitive
behavioral therapy.

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                 MEDIMMUNE, INC.
                                ----------------
                                  (Registrant)



 September 16, 1999             /s/David M. Mott
                                  David M. Mott
                                Vice Chairman and
                                Chief Financial Officer